NHAS
KYTX icon

Novo Holdings A/S’s Kyverna Therapeutics KYTX Stock Holding History

Novo Holdings A/S’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,850,000
Closed -$3.57M – 34
2025
Q1 		$3.57M Hold
1,850,000
– – 0.27% 28
2024
Q4 		$6.92M Hold
1,850,000
– – 0.42% 29
2024
Q3 		$9.05M Buy
1,850,000
+100,000
+6% +$771K 0.45% 31
2024
Q2 		$13.1M Buy
1,750,000
+1,050,000
+150% +$16M 0.71% 30
2024
Q1 		$17.4M Buy
+700,000
New +$19.5M 1.2% 28

Other funds holding KYTX

VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
MPM
MBB Public Markets Chicago, Illinois $839M AUM 20.48% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Novo Holdings A/S's KYTX Position: Q2 2025 in Review

Novo Holdings A/S sold out of Kyverna Therapeutics (KYTX) in Q2 2025, closing a stake of 1,850,000 shares — an estimated $3.57M sold.

Novo Holdings A/S first reported a position in KYTX in Q1 2024 and held it in 5 quarters. The position peaked at $17.4M in Q1 2024. 79 funds tracked by Wall St. Rank hold KYTX as of Q2 2025.

  • Novo Holdings A/S reported no remaining Kyverna Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Novo Holdings A/S sold 1,850,000 Kyverna Therapeutics shares in Q2 2025, an estimated $3.57M.
  • Novo Holdings A/S first reported a position in Kyverna Therapeutics in Q1 2024 and held it in 5 quarters.
  • Novo Holdings A/S's Kyverna Therapeutics position peaked at $17.4M in Q1 2024.
  • 79 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2025.

Based on Novo Holdings A/S's 13F filing for Q2 2025, filed 14 Aug 2025.